CN105175545A - 一种抗vegf-抗pd-1双功能抗体及其应用 - Google Patents
一种抗vegf-抗pd-1双功能抗体及其应用 Download PDFInfo
- Publication number
- CN105175545A CN105175545A CN201510692484.5A CN201510692484A CN105175545A CN 105175545 A CN105175545 A CN 105175545A CN 201510692484 A CN201510692484 A CN 201510692484A CN 105175545 A CN105175545 A CN 105175545A
- Authority
- CN
- China
- Prior art keywords
- vegf
- seqidno
- antibody
- bifunctional antibody
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title claims abstract description 25
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title claims abstract description 24
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- 108010074328 Interferon-gamma Proteins 0.000 claims abstract description 7
- 102100037850 Interferon gamma Human genes 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 3
- 230000001588 bifunctional effect Effects 0.000 claims description 47
- 206010028980 Neoplasm Diseases 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims description 5
- 230000005760 tumorsuppression Effects 0.000 claims description 4
- 238000009098 adjuvant therapy Methods 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000004614 tumor growth Effects 0.000 abstract 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 23
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 239000000427 antigen Substances 0.000 description 10
- 102000036639 antigens Human genes 0.000 description 10
- 108091007433 antigens Proteins 0.000 description 10
- 108010074708 B7-H1 Antigen Proteins 0.000 description 9
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 9
- 238000009169 immunotherapy Methods 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 230000027455 binding Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960003008 blinatumomab Drugs 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108010055044 Tetanus Toxin Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 229940101815 blincyto Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 229940118376 tetanus toxin Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 101150030763 Vegfa gene Proteins 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
Abstract
Description
Kn(105M-1s-1) | Koff(10-5s-1) | Kd(nm) | |
BsAb7-PD-1 | 1.02 | 2.42 | 0.24 |
BsAb8-PD-1 | 0.96 | 2.33 | 0.24 |
BsAb7-VEGF | 1.44 | 2.10 | 0.15 |
BsAb8-VEGF | 1.89 | 2.31 | 0.12 |
抗体浓度 | OD450(BsAb7) | OD450(BsAb8) |
(原液)2μg/ml | 0.096 | 0.107 |
1:3 | 0.101 | 0.110 |
1:9 | 0.323 | 0.323 |
1:27 | 0.733 | 0.802 |
1:81 | 0.852 | 0.831 |
1:243 | 0.857 | 0.854 |
1:729 | 0.898 | 0.866 |
对照/0 | 0.901 | 0.899 |
组别 | 平均瘤重(g) | 平均抑瘤率(%) |
阴性对照 | 2.544±0.316 | / |
BsAb7 | 0.932±0.224 | 63.4 |
BsAb8 | 0.867±0.255 | 65.9 |
贝伐珠单抗 | 0.912±0.213 | 64.2 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510692484.5A CN105175545B (zh) | 2015-10-20 | 2015-10-20 | 一种抗vegf-抗pd-1双功能抗体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510692484.5A CN105175545B (zh) | 2015-10-20 | 2015-10-20 | 一种抗vegf-抗pd-1双功能抗体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105175545A true CN105175545A (zh) | 2015-12-23 |
CN105175545B CN105175545B (zh) | 2019-01-25 |
Family
ID=54898044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510692484.5A Active CN105175545B (zh) | 2015-10-20 | 2015-10-20 | 一种抗vegf-抗pd-1双功能抗体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105175545B (zh) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107383174A (zh) * | 2017-08-21 | 2017-11-24 | 苏州立豪生物科技有限公司 | 一种能与pd‑1特异性结合的肿瘤抑制肽及其用途 |
WO2018036472A1 (zh) * | 2016-08-23 | 2018-03-01 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
WO2018223923A1 (zh) * | 2017-06-05 | 2018-12-13 | 江苏恒瑞医药股份有限公司 | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备***的药物中的用途 |
CN109053895A (zh) * | 2018-08-30 | 2018-12-21 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
CN109069638A (zh) * | 2016-03-24 | 2018-12-21 | 源晟生物制药股份有限公司 | 用于癌症治疗的三特异性抑制剂 |
CN109575140A (zh) * | 2017-09-29 | 2019-04-05 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
US10344090B2 (en) | 2013-12-12 | 2019-07-09 | Shanghai Hangrui Pharmaceutical Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
WO2019154349A1 (zh) * | 2018-02-11 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗vegf天然抗体结构样异源二聚体形式双特异抗体及其制备 |
CN110498857A (zh) * | 2019-08-09 | 2019-11-26 | 安徽瀚海博兴生物技术有限公司 | 一种新型结构的抗vegf-抗pd1双特异性抗体 |
CN110563849A (zh) * | 2019-08-09 | 2019-12-13 | 安徽瀚海博兴生物技术有限公司 | 一种全新序列的抗vegf-抗pd1双特异性抗体 |
CN110869392A (zh) * | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
WO2021026685A1 (zh) * | 2019-08-09 | 2021-02-18 | 安徽瀚海博兴生物技术有限公司 | 一种新型结构的抗vegf-抗pd1双特异性抗体 |
WO2021104302A1 (zh) * | 2019-11-25 | 2021-06-03 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双特异性抗体、其药物组合物及其用途 |
US11319378B2 (en) | 2016-11-18 | 2022-05-03 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same |
WO2022206843A1 (en) * | 2021-03-31 | 2022-10-06 | Wuxi Biologics (Shanghai) Co., Ltd. | A bispecific anti-pd-l1/vegf antibody and uses thereof |
US11479608B2 (en) | 2016-08-23 | 2022-10-25 | Akeso Biopharma, Inc. | Anti-CTLA4 antibodies |
US11498977B2 (en) | 2016-09-29 | 2022-11-15 | Beijing Hanmi Pharmaceutical Co., Ltd. | Heterodimeric immunoglobulin constructs and preparation methods thereof |
EP3954712A4 (en) * | 2019-04-01 | 2022-12-07 | Huabo Biopharm (Shanghai) Co., Ltd. | BIFUNCTIONAL ANTI-PD-L1/VEGF ANTIBODIES AND THEIR USE |
US11578128B2 (en) | 2016-08-23 | 2023-02-14 | Akeso Pharmaceuticals, Inc. | Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof |
US11753471B2 (en) | 2018-02-08 | 2023-09-12 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104945508A (zh) * | 2007-06-18 | 2015-09-30 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
CN104974260A (zh) * | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗hgf/vegf双特异性抗体、其制备方法及应用 |
-
2015
- 2015-10-20 CN CN201510692484.5A patent/CN105175545B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104945508A (zh) * | 2007-06-18 | 2015-09-30 | 默沙东有限责任公司 | 针对人程序性死亡受体pd-1的抗体 |
CN104974260A (zh) * | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗hgf/vegf双特异性抗体、其制备方法及应用 |
Non-Patent Citations (2)
Title |
---|
YASUDA S ET AL: "Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor2(VEGFR2) induces synergistic anti-tumor effect in vivo", 《CLINICAL & EXPERIMENTAL IMMUNOLOGY》 * |
王倩: "PD-1-VEGF 多靶向Fc 融合蛋白PVP 的表达、纯化及初步功能研究", 《中国优秀硕士学位论文全文数据库》 * |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10344090B2 (en) | 2013-12-12 | 2019-07-09 | Shanghai Hangrui Pharmaceutical Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
US11365255B2 (en) | 2013-12-12 | 2022-06-21 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
EP3432927A4 (en) * | 2016-03-24 | 2019-11-20 | Gensun Biopharma Inc. | TRIPLE-SPECIFIC INHIBITORS FOR CANCER TREATMENT |
CN109069638A (zh) * | 2016-03-24 | 2018-12-21 | 源晟生物制药股份有限公司 | 用于癌症治疗的三特异性抑制剂 |
US11578128B2 (en) | 2016-08-23 | 2023-02-14 | Akeso Pharmaceuticals, Inc. | Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof |
WO2018036472A1 (zh) * | 2016-08-23 | 2018-03-01 | 中山康方生物医药有限公司 | 一种抗pd1单克隆抗体、其药物组合物及其用途 |
US11479608B2 (en) | 2016-08-23 | 2022-10-25 | Akeso Biopharma, Inc. | Anti-CTLA4 antibodies |
US11498977B2 (en) | 2016-09-29 | 2022-11-15 | Beijing Hanmi Pharmaceutical Co., Ltd. | Heterodimeric immunoglobulin constructs and preparation methods thereof |
US11319378B2 (en) | 2016-11-18 | 2022-05-03 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same |
CN110869392A (zh) * | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
WO2018223923A1 (zh) * | 2017-06-05 | 2018-12-13 | 江苏恒瑞医药股份有限公司 | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备***的药物中的用途 |
CN109963592A (zh) * | 2017-06-05 | 2019-07-02 | 江苏恒瑞医药股份有限公司 | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备***的药物中的用途 |
CN107383174A (zh) * | 2017-08-21 | 2017-11-24 | 苏州立豪生物科技有限公司 | 一种能与pd‑1特异性结合的肿瘤抑制肽及其用途 |
CN109575140B (zh) * | 2017-09-29 | 2021-02-23 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
CN109575140A (zh) * | 2017-09-29 | 2019-04-05 | 北京比洋生物技术有限公司 | 靶向pd-1或pd-l1且靶向vegf家族的双靶向融合蛋白及其用途 |
US11753471B2 (en) | 2018-02-08 | 2023-09-12 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-PD-1/anti-HER2 natural antibody structural heterodimeric bispecific antibody and method of preparing same |
WO2019154349A1 (zh) * | 2018-02-11 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗vegf天然抗体结构样异源二聚体形式双特异抗体及其制备 |
EP3750920A4 (en) * | 2018-02-11 | 2021-11-10 | Beijing Hanmi Pharmaceutical Co., Ltd. | BISPECIFIC ANTIBODY IN HETERODIMER FORM SIMILAR TO A NATURAL ANTI-PD-1 / ANTI-VEGF ANTIBODY STRUCTURE AND PRODUCTION OF IT |
CN111712522A (zh) * | 2018-02-11 | 2020-09-25 | 北京韩美药品有限公司 | 抗pd-1/抗vegf天然抗体结构样异源二聚体形式双特异抗体及其制备 |
US20210040193A1 (en) * | 2018-02-11 | 2021-02-11 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-pd-1/anti-vegf natural antibody structure like heterodimeric form bispecific antibody and preparation thereof |
JP2021512624A (ja) * | 2018-02-11 | 2021-05-20 | ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッドBeijing Hanmi Pharmaceutical Co., Ltd. | 抗pd−1/抗vegf天然抗体構造様ヘテロ二量体型二重特異性抗体及びその製造 |
US11827697B2 (en) | 2018-02-11 | 2023-11-28 | Beijing Hanmi Pharmaceutical Co., Ltd. | Anti-PD-1/anti-VEGF natural antibody structure like heterodimeric form bispecific antibody and preparation thereof |
JP7374995B2 (ja) | 2018-08-30 | 2023-11-07 | 中山康方生物医▲藥▼有限公司 | 抗pd-1/抗vegfa二官能性抗体、その医薬組成物およびその使用 |
CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
JP2021536242A (ja) * | 2018-08-30 | 2021-12-27 | 中山康方生物医▲藥▼有限公司Akeso Biopharma, Inc. | 抗pd−1/抗vegfa二官能性抗体、その医薬組成物およびその使用 |
US20210340239A1 (en) * | 2018-08-30 | 2021-11-04 | Akeso Biopharma, Inc. | Anti-pd-1/vegfa bifunctional antibody, pharmaceutical composition thereof and use thereof |
CN109053895A (zh) * | 2018-08-30 | 2018-12-21 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
WO2020043184A1 (zh) | 2018-08-30 | 2020-03-05 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
EP3954712A4 (en) * | 2019-04-01 | 2022-12-07 | Huabo Biopharm (Shanghai) Co., Ltd. | BIFUNCTIONAL ANTI-PD-L1/VEGF ANTIBODIES AND THEIR USE |
WO2021026685A1 (zh) * | 2019-08-09 | 2021-02-18 | 安徽瀚海博兴生物技术有限公司 | 一种新型结构的抗vegf-抗pd1双特异性抗体 |
CN110563849B (zh) * | 2019-08-09 | 2022-09-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd1双特异性抗体 |
CN110498857B (zh) * | 2019-08-09 | 2022-09-09 | 安徽瀚海博兴生物技术有限公司 | 一种抗vegf-抗pd1双特异性抗体 |
JP2021535193A (ja) * | 2019-08-09 | 2021-12-16 | 安徽瀚海博▲シィン▼生物技▲シゥー▼有限公司 | 新型構造の抗vegf−抗pd1二重特異性抗体 |
CN110563849A (zh) * | 2019-08-09 | 2019-12-13 | 安徽瀚海博兴生物技术有限公司 | 一种全新序列的抗vegf-抗pd1双特异性抗体 |
US11661454B2 (en) | 2019-08-09 | 2023-05-30 | Anhui Biox Vision Biological Technology Co., Ltd. | Anti-VEGF-PD1 bispecific antibody with novel structure and use thereof |
CN110498857A (zh) * | 2019-08-09 | 2019-11-26 | 安徽瀚海博兴生物技术有限公司 | 一种新型结构的抗vegf-抗pd1双特异性抗体 |
JP7052149B2 (ja) | 2019-08-09 | 2022-04-11 | 安徽瀚海博▲シィン▼生物技▲シゥー▼有限公司 | 新型構造の抗vegf-抗pd1二重特異性抗体 |
WO2021104302A1 (zh) * | 2019-11-25 | 2021-06-03 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双特异性抗体、其药物组合物及其用途 |
WO2022206843A1 (en) * | 2021-03-31 | 2022-10-06 | Wuxi Biologics (Shanghai) Co., Ltd. | A bispecific anti-pd-l1/vegf antibody and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN105175545B (zh) | 2019-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105175545A (zh) | 一种抗vegf-抗pd-1双功能抗体及其应用 | |
US11292841B2 (en) | Anti-PD-1 nano-antibody and application thereof | |
EP3954712A1 (en) | Anti-pd-l1/vegf bifunctional antibody and use thereof | |
US10815303B2 (en) | Fusion protein for restoring the functions of failing immune cells and application thereof | |
US10118964B2 (en) | Construction and application of bispecific antibody HER2xCD3 | |
WO2022121239A1 (zh) | 一种双特异性抗体及其应用 | |
JP7262597B2 (ja) | 二重特異性抗体及びその作製方法と使用 | |
CN105296433A (zh) | 一种ctla4抗体、其药物组合物及其用途 | |
CN105121474A (zh) | 融合免疫调节蛋白及其制备方法 | |
CN105175544A (zh) | 一种抗pd-1人源化单克隆抗体及其应用 | |
CN107312093A (zh) | 血管内皮生长因子融合蛋白 | |
CN110386987B (zh) | 一种抑制性的合成Notch和双靶点***及其制备方法和应用 | |
CN103965362B (zh) | 一种可使t细胞趋向肿瘤部位的嵌合趋化因子受体 | |
CN104829725A (zh) | 一种双特异性抗体cd133×cd3的构建及应用 | |
CN115335407A (zh) | 结合cd19的嵌合抗原受体及其用途 | |
CN110194799A (zh) | 结合犬pd-1的抗犬pd-1抗体 | |
CN110305906A (zh) | 一种靶向pdl1的car嵌合受体的慢病毒载体及pdl1-car-t细胞 | |
CN105713094B (zh) | 一种cd24抗体融合蛋白的设计及其应用 | |
CN104059148A (zh) | 人源化抗人表皮生长因子受体抗体及其应用 | |
CN104558193A (zh) | 一种靶向鼠t淋巴细胞cd3和人肿瘤抗原her2的双特异性抗体制备方法及应用 | |
CN101619305B (zh) | 抗人cd52单克隆抗体杂交瘤细胞系、单克隆抗体、工程抗体、载体、试剂盒及其用途 | |
CN113980133B (zh) | 抗体及其在抗肿瘤中的应用 | |
CN111848806B (zh) | Egfr-cd3双功能抗体及其应用 | |
CN112375136B (zh) | Ny-eso-1特异性t细胞受体筛选及其抗肿瘤用途 | |
CN112679615A (zh) | 一种融合蛋白 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20151223 Assignee: Anhui Xingtai Financial Leasing Co.,Ltd. Assignor: ANHUI RUBIOX-VISION BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2021340000011 Denomination of invention: A bifunctional antibody against vegf-pd-1 and its application Granted publication date: 20190125 License type: Exclusive License Record date: 20210609 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A bifunctional antibody against vegf-pd-1 and its application Effective date of registration: 20210616 Granted publication date: 20190125 Pledgee: Anhui Xingtai Financial Leasing Co.,Ltd. Pledgor: ANHUI RUBIOX-VISION BIOTECHNOLOGY Co.,Ltd. Registration number: Y2021980004776 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220718 Granted publication date: 20190125 Pledgee: Anhui Xingtai Financial Leasing Co.,Ltd. Pledgor: ANHUI RUBIOX-VISION BIOTECHNOLOGY Co.,Ltd. Registration number: Y2021980004776 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Anhui Xingtai Financial Leasing Co.,Ltd. Assignor: ANHUI RUBIOX-VISION BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2021340000011 Date of cancellation: 20220801 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20151223 Assignee: Anhui Xingtai Financial Leasing Co.,Ltd. Assignor: ANHUI RUBIOX-VISION BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2023980035207 Denomination of invention: A Bifunctional Antibody Against VEGF and PD-1 and Its Application Granted publication date: 20190125 License type: Exclusive License Record date: 20230508 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Bifunctional Antibody Against VEGF and PD-1 and Its Application Effective date of registration: 20230509 Granted publication date: 20190125 Pledgee: Anhui Xingtai Financial Leasing Co.,Ltd. Pledgor: ANHUI RUBIOX-VISION BIOTECHNOLOGY Co.,Ltd. Registration number: Y2023980040122 |